XML 68 R46.htm IDEA: XBRL DOCUMENT v3.23.1
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Company's Revenue for Reportable Segment by Country Based on Locations of Customer

The following represents the Company’s revenue for its reportable segment by country, based on the locations of the customer (in thousands).

 

 

 

For the Year Ended December 31, 2022

 

 

 

Oncology
Innovation
Platform

 

 

Commercial
Platform

 

 

Consolidated
Total

 

United States

 

$

8,099

 

 

$

87,977

 

 

$

96,076

 

Spain

 

 

4,735

 

 

 

 

 

 

4,735

 

Other Foreign Countries

 

 

2,010

 

 

 

 

 

 

2,010

 

Total Revenue

 

$

14,844

 

 

$

87,977

 

 

$

102,821

 

 

 

 

 

For the Year Ended December 31, 2021

 

 

 

Oncology
Innovation
Platform

 

 

Commercial
Platform

 

 

Consolidated
Total

 

United States

 

$

22,206

 

 

$

66,992

 

 

$

89,198

 

Spain

 

 

5,289

 

 

 

 

 

 

5,289

 

Other foreign countries

 

 

882

 

 

 

 

 

 

882

 

Total Revenue

 

$

28,377

 

 

$

66,992

 

 

$

95,369

 

 

Summary of Receivables and Contract Liabilities From Contracts with Customers

The following table provides information about receivables and contract liabilities from contracts with customers. The Company has not recorded any contract assets from contracts with customers (in thousands).

 

 

 

December 31,

 

 

 

2022

 

 

2021

 

Accounts receivable, gross

 

$

67,011

 

 

$

54,716

 

Chargebacks and other deductions

 

 

(29,470

)

 

 

(22,869

)

Provision for credit losses

 

 

(9,676

)

 

 

(9,069

)

Accounts receivable, net

 

$

27,865

 

 

$

22,778

 

Deferred revenue

 

 

2,823

 

 

 

2,798

 

Total contract liabilities

 

$

2,823

 

 

$

2,798

 

Summary of Accounts Receivable by Reportable Segments

The following tables illustrate accounts receivable by reportable segments (in thousands).

 

 

 

December 31, 2022

 

 

 

Oncology
Innovation
Platform

 

 

Commercial
Platform

 

 

Consolidated
Total

 

Accounts receivable, gross

 

$

14,520

 

 

$

52,491

 

 

$

67,011

 

Chargebacks and other deductions

 

 

 

 

 

(29,470

)

 

 

(29,470

)

Provision for credit losses

 

 

(9,444

)

 

 

(232

)

 

 

(9,676

)

Accounts receivable, net

 

$

5,076

 

 

$

22,789

 

 

$

27,865

 

 

 

 

 

December 31, 2021

 

 

 

Oncology
Innovation
Platform

 

 

Commercial
Platform

 

 

Consolidated
Total

 

Accounts receivable, gross

 

$

10,418

 

 

$

44,298

 

 

$

54,716

 

Chargebacks and other deductions

 

 

 

 

 

(22,869

)

 

 

(22,869

)

Provision for credit losses

 

 

(8,972

)

 

 

(97

)

 

 

(9,069

)

Accounts receivable, net

 

$

1,446

 

 

$

21,332

 

 

$

22,778